Blockchain News - 11/16/2026 4:31:54 PM - GMT (+0 )
Eli Lilly (LLY) is still pressing higher in a firmly bullish structure, with the current price at $1,457.43, above the 7-day, 20-day, 50-day, 12-day EMA and 26-day EMA. That matters because the moving-average stack remains constructive: MA7 sits above MA20, which sits above MA50, a classic trend-confirmation pattern rather than a reflex bounce.
The problem is that the stock is also running close to resistance. The 24-hour range reached $1,461.78 on the high side, while immediate resistance is marked at $1,470.21 and strong resistance at $1,483.00. With RSI at 70.02 and price sitting near the upper Bollinger Band at $1,482.34, the setup is extended even if the broader trend remains intact.
What the latest company news changedLilly’s own third-quarter 2026 update, released October 29, is the fundamental anchor here. Revenue rose 39% to $24.4 billion, driven mainly by Mounjaro and Zepbound, and the company raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0 billion to $92.0 billion. It also increased underlying non-GAAP EPS guidance at the midpoint by $4.07, according to Lilly’s release.
That is the kind of earnings reset that can support a higher stock price, but the market has already responded aggressively. The current technical posture suggests the easy part of the move may have happened first, while the next leg depends on whether buyers can prove they still have sponsorship above the $1,470 area.
Analyst targets are rising, but the stock is already close to themJefferies raised its price target on Eli Lilly to $1,700 from $1,610 on November 9, 2026, and kept a Buy rating, arguing that the Street underestimates the GLP-1 opportunity outside the U.S. That target sits well above the current share price and reinforces the bullish earnings narrative.
Separately, stockanalysis.com cited 31 analysts polled by S&P Global with a consensus Buy rating and an average target of $1,463. That average is barely above the current price, which tells you the market is not dealing with a deep-discount setup; it is dealing with a high-multiple leader where the path higher is still open, but no longer cheap.
Technical read: bullish structure, weaker confirmationSeveral indicators point in the same direction, but not all of them are equally supportive.
- MA structure is strongly bullish.
- %B at 0.8349 shows price is near the top of the recent Bollinger envelope.
- Stochastic %K at 78.65 also reflects late-stage strength.
- MACD histogram at 0.0000 is flat, which weakens the momentum story.
- Daily ATR(14) at $39.21 means the stock can still move sharply in either direction.
The volume backdrop is the key caution flag. Reported volume is 0.40x versus the 5-day average, which means the bounce lacks full confirmation. In plain terms, Lilly is pushing into resistance without the kind of trading intensity that usually gives a breakout more durability.
Binance Futures positioning: cautious, not euphoricOn Binance perpetual futures, the funding rate is neutral at 0.0000%, so there is no obvious cost pressure forcing one side of the trade. Open interest slipped 1.38% over 24 hours to 2,188.85 contracts, which points to slightly reduced participation rather than aggressive speculative buildup.
The long/short ratios lean bearish in Binance cohorts: global accounts show 40.9% long and 59.1% short, while top-trader accounts show 39.1% long and 60.9% short, both observed at 2026-11-16 10:00 UTC. That is a positioning read, not a verdict on the stock itself. It suggests traders on that venue are leaning against the move even as taker flow is positive, with the taker buy/sell ratio at 1.2709.
Levels that matter from hereImmediate support is $1,436.21, with stronger support at $1,415.00. A clean hold above the pivot at $1,449.00 keeps the trend intact. If the stock loses the $1,436 area, the market would be telling you the latest push is running out of sponsorship before it can challenge the $1,470-$1,483 band again.
The upside case is straightforward: sustained trade above immediate resistance opens the door to a retest of strong resistance and, beyond that, higher analyst-based valuation support. The downside case is equally clear: overbought momentum, light volume, and flat MACD make the current price vulnerable to a pullback toward the 20-day average and the lower support shelf if buyers fail to follow through.
read more


